$3.75 Million in Sales Expected for Voyager Therapeutics Inc (NASDAQ:VYGR) This Quarter
Equities analysts expect Voyager Therapeutics Inc (NASDAQ:VYGR) to announce $3.75 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Voyager Therapeutics’ earnings, with estimates ranging from $2.00 million to $5.00 million. Voyager Therapeutics posted sales of $2.58 million in the same quarter last year, which would indicate a positive year over year growth rate of 45.3%. The firm is expected to report its next quarterly earnings results on Tuesday, August 6th.
On average, analysts expect that Voyager Therapeutics will report full year sales of $25.14 million for the current fiscal year, with estimates ranging from $5.00 million to $81.57 million. For the next year, analysts anticipate that the firm will report sales of $43.37 million, with estimates ranging from $7.60 million to $95.57 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Voyager Therapeutics.
Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.81) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.65 by ($1.46). The firm had revenue of $5.20 million for the quarter, compared to the consensus estimate of $3.00 million. Voyager Therapeutics had a negative return on equity of 129.67% and a negative net margin of 804.55%.
Shares of NASDAQ:VYGR opened at $23.53 on Thursday. The stock has a market cap of $866.66 million, a price-to-earnings ratio of -8.56 and a beta of 2.47. Voyager Therapeutics has a 1-year low of $7.76 and a 1-year high of $25.74.
Several institutional investors have recently bought and sold shares of the company. SG3 Management LLC bought a new stake in shares of Voyager Therapeutics in the first quarter valued at $57,000. Metropolitan Life Insurance Co. NY raised its stake in shares of Voyager Therapeutics by 449.4% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock valued at $85,000 after buying an additional 7,401 shares during the period. BNP Paribas Arbitrage SA raised its stake in shares of Voyager Therapeutics by 74,766.7% in the first quarter. BNP Paribas Arbitrage SA now owns 4,492 shares of the company’s stock valued at $86,000 after buying an additional 4,486 shares during the period. Bank of America Corp DE raised its stake in shares of Voyager Therapeutics by 211.0% in the fourth quarter. Bank of America Corp DE now owns 10,637 shares of the company’s stock valued at $100,000 after buying an additional 7,217 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in shares of Voyager Therapeutics by 66.8% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,380 shares of the company’s stock valued at $101,000 after buying an additional 4,559 shares during the period. Institutional investors own 73.78% of the company’s stock.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.
Further Reading: How Do Mutual Funds Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.